An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer

References

• Bray F , Ferlay J , Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Ward EM , Sherman RL , Henley SJ , et al. Annual report to the nation on the status of cancer, featuring cancer in men and women age 20-49 years. J Natl Cancer Inst. 2019 Dec 1;111(12):1279–1297.
   PubMedGoogle Scholar
• Siegel RL , Miller KD , Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Sopik V , Iqbal J , Rosen B , et al. Why have ovarian cancer mortality rates declined? Part I. Incidence. Gynecol Oncol. 2015 Sep;138(3):741–749.
   PubMed Web of Science ®Google Scholar
• Sopik V , Iqbal J , Rosen B , et al. Why have ovarian cancer mortality rates declined? Part II. Case-fatality. Gynecol Oncol. 2015 Sep;138(3):750–756.
   PubMed Web of Science ®Google Scholar
• Chang SJ , Hodeib M , Chang J , et al. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013 Sep;130(3):493–498.
   PubMed Web of Science ®Google Scholar
• Monk BJ , Randall LM , Grisham RN. The evolving landscape of chemotherapy in newly diagnosed advanced epithelial ovarian cancer. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e141–e151.
   PubMedGoogle Scholar
• Sopik V , Rosen B , Giannakeas V , et al. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecol Oncol 2015 Sep;138(3):757–761.
   PubMed Web of Science ®Google Scholar
• Dedrick RL , Myers CE , Bungay PM , et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978 Jan;62(1):1–11.
   PubMedGoogle Scholar
• Jaaback K , Johnson N , Lawrie TA . Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016 Jan;12(1):CD005340.
   Google Scholar
• Weisberger AS , Levine B , Storaasli JP . Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc. 1955 Dec 31;159(18):1704–1707.
   PubMed Web of Science ®Google Scholar
• Flessner MF . The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005 Mar;288(3):F433–42.
   PubMed Web of Science ®Google Scholar
• van der Speeten K , Stuart OA , Sugarbaker PH . Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009 May-Jun;15(3):216–224.
   PubMed Web of Science ®Google Scholar
• de Bree E , Michelakis D , Stamatiou D , et al. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017 Jun 1; 2(2):47–62.
   PubMed Web of Science ®Google Scholar
• de Bree E , Tsiftsis DD . Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res. 2007;169:39–51.
   PubMedGoogle Scholar
• de Lima Vazquez V , Stuart OA , Mohamed F , et al. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003 Aug;52(2):108–112.
   PubMed Web of Science ®Google Scholar
• de Bree E , Tsiftsis DD . Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. Recent Results Cancer Res. 2007;169:53–73.
   PubMedGoogle Scholar
• Speyer JL , Sugarbaker PH , Collins JM , et al. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 1981 May;41(5):1916–1922.
   PubMed Web of Science ®Google Scholar
• Lindnér P , Heath DD , Shalinsky DR , et al. Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide. Surg Oncol. 1993;2(2):105–112.
   PubMed Web of Science ®Google Scholar
• Landrum LM , Java J , Mathews CA , et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jul;130(1):12–18.
   PubMed Web of Science ®Google Scholar
• Steuperaert M , Debbaut C , Segers P , et al. Modelling drug transport during intraperitoneal chemotherapy. Pleura Peritoneum. 2017 Jun 1;2(2):73–83.
   PubMed Web of Science ®Google Scholar
• Eisenkop SM , Spirtos NM , Friedman RL , et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003 Aug;90(2):390–396.
   PubMed Web of Science ®Google Scholar
• Eisenkop SM , Spirtos NM , Lin WC . “Optimal” cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol. 2006 Oct;103(1):329–335.
   PubMed Web of Science ®Google Scholar
• de Bree E . Optimal drugs for HIPEC in different tumors. J BUON. 2015 May;20(Suppl 1):S40–6.
   PubMedGoogle Scholar
• de Bree E , Helm CW . Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. Expert Rev Anticancer Ther. 2012 Jul;12(7):895–911.
   PubMed Web of Science ®Google Scholar
• Spiliotis J , Halkia E , de Bree E . Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives. Curr Oncol. 2016 Jun;23(3):e266–75.
   PubMed Web of Science ®Google Scholar
• Kyrgiou M , Salanti G , Pavlidis N , et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 2006 Nov 15;98(22):1655–1663.
   PubMedGoogle Scholar
• Alberts DS , Hannigan EV , Liu PY , et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol Oncol. 2006 Jan;100(1):133–138.
   PubMed Web of Science ®Google Scholar
• Markman M , Bundy BN , Alberts DS , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001–1007.
   PubMed Web of Science ®Google Scholar
• Armstrong DK , Bundy B , Wenzel L , et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34–43.
   PubMed Web of Science ®Google Scholar
• Jaaback K , Johnson N . Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2006 Jan;25(1):CD005340.
   Google Scholar
• Trimble EL , Christian MC . Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2006 Jan;100(1):3–4.
   PubMed Web of Science ®Google Scholar
• Tewari D , Java JJ , Salani R , et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2015 May 1;33(13):1460–1466.
   PubMed Web of Science ®Google Scholar
• Shi T , Jiang R , Pu H , et al. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study. Br J Cancer. 2019 Aug;121(5):425–428.
   PubMed Web of Science ®Google Scholar
• Walker JL , Brady MF , Wenzel L , et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 Jun 1;37(16):1380–1390.
   PubMed Web of Science ®Google Scholar
• Provencher DM , Gallagher CJ , Parulekar WR , et al. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol. 2018 Feb 1;29(2):431–438.
   PubMed Web of Science ®Google Scholar
• Chan JK , Brady MF , Penson RT , et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016 Feb 25;374(8):738–748.
   PubMed Web of Science ®Google Scholar
• Wright AA , Bohlke K , Armstrong DK , et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of Gynecologic Oncology and American Society of Clinical Oncology Clinical practice guideline. J Clin Oncol. 2016 Oct 1;34(28):3460–3473.
   PubMed Web of Science ®Google Scholar
• Vergote I , Tropé CG , Amant F , et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943–953.
   PubMed Web of Science ®Google Scholar
• Kehoe S , Hook J , Nankivell M , et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015 Jul 18;386(9990):249–257.
   PubMed Web of Science ®Google Scholar
• Piccart MJ , Floquet A , Scarfone G , et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003;Nov-Dec;13(Suppl 2):196–203.
   Google Scholar
• Fujiwara K , Armstrong D , Morgan M , et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007 Jan-Feb;17(1):1–20.
   PubMed Web of Science ®Google Scholar
• Helm CW . Ports and complications for intraperitoneal chemotherapy delivery. BJOG. 2012 Jan;119(2):150–159.
   PubMed Web of Science ®Google Scholar
• Wright AA , Cronin A , Milne DE , et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2015 Sep 10;33(26):2841–2847.
   PubMed Web of Science ®Google Scholar
• Gourley C , Walker JL , Mackay HJ . Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book. 2016;35:143–151.
   PubMedGoogle Scholar
• Monk BJ , Chan JK . Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? Ann Oncol. 2017 Nov 1;28(Suppl. 8):viii40–viii45.
   PubMedGoogle Scholar
• Markman M . Chemotherapy: limited use of the intraperitoneal route for ovarian cancer-why? Nat Rev Clin Oncol. 2015 Nov;12(11):628–630.
   PubMed Web of Science ®Google Scholar
• Robinson WR , Beyer J . Factors affecting the completion of intraperitoneal chemotherapy in women with ovarian cancer. Int J Gynecol Cancer. 2010 Jan;20(1):70–74.
   PubMed Web of Science ®Google Scholar
• Lesnock JL , Richard SD , Zorn KK , et al. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecol Oncol. 2010 Mar;116(3):345–350.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 3.2019. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf, cited 2019 Dec 27 .
   Google Scholar
• Elit L , Oliver TK , Covens A , et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer. 2007 Feb 15;109(4):692–702.
   PubMed Web of Science ®Google Scholar
• de Bree E , Romanos J , Tsiftsis DD . Hyperthermia in anticancer treatment. Eur J Surg Oncol. 2002 Feb;28(1):95.
   PubMedGoogle Scholar
• Urano M , Kuroda M , Nishimura Y . For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia. 1999 Mar-Apr;15(2):79–107.
   PubMed Web of Science ®Google Scholar
• Lepock JR . How do cells respond to their thermal environment? Int J Hyperthermia. 2005 Dec;21(8):681–687.
   PubMed Web of Science ®Google Scholar
• Toraya-Brown S , Fiering S . Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia. 2014 Dec;30(8):531–539.
   PubMed Web of Science ®Google Scholar
• Shiu MH , Fortner JG . Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res. 1980 Nov;40(11):4081–4084.
   PubMed Web of Science ®Google Scholar
• Sticca RP , Dach BW . Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003 Jul;12(3):689–701.
   PubMedGoogle Scholar
• Storm FK . Clinical hyperthermia and chemotherapy. Radiol Clin North Am. 1989 May;27(3):621–627.
   PubMed Web of Science ®Google Scholar
• Takemoto M , Kuroda M , Urano M , et al. The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia. 2003 Mar-Apr;19(2):193–203.
   PubMed Web of Science ®Google Scholar
• Zunino B , Rubio-Patiño C , Villa E , et al. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene. 2016 Jan 14;35(2):261–268.
   PubMed Web of Science ®Google Scholar
• Michalakis J , Georgatos SD , de Bree E , et al. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. Ann Surg Oncol. 2007 Mar;14(3):1220–1228.
   PubMed Web of Science ®Google Scholar
• Rupniak HT , Whelan RD , Hill BT . Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro. Int J Cancer. 1983 Jul 15;32(1):7–12.
   PubMed Web of Science ®Google Scholar
• Alberts DS , Young L , Mason N , et al. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol. 1985 Sep;12(3 Suppl 4):38–42.
   PubMed Web of Science ®Google Scholar
• Link KH , Leder G , Pillasch J , et al. In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin Surg Oncol. 1998 Apr-May;14(3):189–201.
   PubMedGoogle Scholar
• Chua TC , Yan TD , Saxena A , et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009 Jun;249(6):900–907.
   PubMed Web of Science ®Google Scholar
• Hotouras A , Desai D , Bhan C , et al. Heated IntraPEritoneal Chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. Int J Gynecol Cancer. 2016 May;26(4):661–670.
   PubMed Web of Science ®Google Scholar
• Wang Y , Ren F , Chen P , et al. Effects of cytoreductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus cytoreductive surgery for ovarian cancer patients: A systematic review and meta-analysis. Eur J Surg Oncol. 2019 Mar;45(3):301–309.
   PubMed Web of Science ®Google Scholar
• Mulier S , Claes JP , Dierieck V , et al. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012;18(25):3793–3803.
   PubMed Web of Science ®Google Scholar
• Helm CW , Richard SD , Pan J , et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010 Jan;20(1):61–69.
   PubMed Web of Science ®Google Scholar
• Halkia E , Spiliotis J , Sugarbaker P . Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract. 2012;2012:541842.
   PubMed Web of Science ®Google Scholar
• Cowan RA , O’Cearbhaill RE , Zivanovic O , et al. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperthermia. 2017 Aug;33(5):548–553.
   PubMed Web of Science ®Google Scholar
• Zivanovic O , Chi DS , Filippova O , et al. It’s time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2018 Dec;151(3):555–561.
   PubMed Web of Science ®Google Scholar
• Bakrin N , Bereder JM , Decullier E , et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013 Dec;39(12):1435–1443.
   PubMed Web of Science ®Google Scholar
• Classe JM , Glehen O , Decullier E , et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer. Anticancer Res. 2015 Sep;35(9):4997–5005.
   PubMed Web of Science ®Google Scholar
• Muñoz-Casares FC , Medina-Fernández FJ , Arjona-Sánchez Á , et al. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center. Eur J Surg Oncol. 2016 Feb;42(2):224–233.
   PubMed Web of Science ®Google Scholar
• Ceresoli M , Verrengia A , Montori G , et al. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study. J Gynecol Oncol. 2018 May;29(3):e53.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos PA , Gil J , Gil E , et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol. 2014 Jul;21(7):2383–2389.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos PA , Gil J , Feliciangeli E , et al. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol. 2015 Mar;22(3):987–993.
   PubMed Web of Science ®Google Scholar
• Fagotti A , Costantini B , Petrillo M , et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012 Dec;127(3):502–505.
   PubMed Web of Science ®Google Scholar
• Petrillo M , De Iaco P , Cianci S , et al. Long-term survival for platinum-sensitive recurrent ovarian cancer patients treated with secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016 May;23(5):1660–1665.
   PubMed Web of Science ®Google Scholar
• Harrison ML , Gore ME , Spriggs D , et al. Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol Oncol. 2007 Sep;106(3):469–475.
   PubMed Web of Science ®Google Scholar
• Rettenmaier MA , Micha JP , Bohart R , et al. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 2020 Jan;244:101–105.
   PubMed Web of Science ®Google Scholar
• Mendivil AA , Rettenmaier MA , Abaid LN , et al. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol. 2017 Aug;80(2):405–410.
   PubMed Web of Science ®Google Scholar
• Kim SI , Cho J , Lee EJ , et al. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Dec;98(50):e18355.
   PubMed Web of Science ®Google Scholar
• Lim MC , Chang S-J , Yoo HJ , et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol. 2017 May 20;35(suppl 15): 5520.
   Google Scholar
• van Driel WJ , Koole SN , Sikorska K , et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018 Jan 18;378(3):230–240.
   PubMed Web of Science ®Google Scholar
• Koole SN , van Driel WJ , Sonke GS . Hyperthermic intraperitoneal chemotherapy for ovarian cancer: the heat is on. Cancer. 2019 Dec 15;125(Suppl 24):4587–4593.
   PubMedGoogle Scholar
• Koole SN , Kieffer JM , Sikorska K , et al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. Eur J Surg Oncol. 2019 May 13. pii: S0748-7983(19)30444-5. DOI: 10.1016/j.ejso.2019.05.006. Epub ahead of print.
   PubMedGoogle Scholar
• Koole SN , van Lieshout C , van Driel WJ , et al. Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial. J Clin Oncol. 2019 Aug 10;37(23):2041–2050.
   PubMed Web of Science ®Google Scholar
• Vergote I , Harter P , Chiva L . Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. Cancer. 2019 Dec 15;125(Suppl 24):4594–4597.
   PubMedGoogle Scholar
• Spiliotis J , Halkia E , Lianos E , et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015 May;22(5):1570–1575.
   PubMed Web of Science ®Google Scholar
• Harter P , Reuss A , Sehouli J , et al. Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al. Int J Gynecol Cancer. 2017 Feb;27(2):246–247.
   PubMed Web of Science ®Google Scholar
• Batista TP . Comment on: surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2017 Dec;24(Suppl 3):630.
   PubMedGoogle Scholar
• Sanz Rubiales Á , Del Valle ML . Survival analysis in a randomized trial of HIPEC in ovarian cancer. Ann Surg Oncol. 2017 Dec;24(Suppl 3):631.
   PubMedGoogle Scholar
• Clinical Trials.Gov https://clinicaltrials.gov/, visited January 6, 2020
   Google Scholar
• Koole S , van Stein R , Sikorska K , et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020. pii: ijgc-2020-001231. DOI: 10.1136/ijgc-2020-001231. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• de Bree E , Rosing H , Filis D , et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008 Apr;15(4):1183–1192.
   PubMed Web of Science ®Google Scholar
• de Bree E , Rosing H , Beijnen JH , et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs. 2003 Feb;14(2):103–110.
   PubMed Web of Science ®Google Scholar
• de Bree E , Theodoropoulos PA , Rosing H , et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev. 2006 Oct;32(6):471–482.
   PubMed Web of Science ®Google Scholar
• Kitayama J , Ishigami H , Yamaguchi H , et al. Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model. Pleura Peritoneum. 2017 Jun 1;2(2):95–102.
   PubMed Web of Science ®Google Scholar
• Alyami M , Hübner M , Grass F , et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019 Jul;20(7):e368–e377.
   PubMed Web of Science ®Google Scholar
• Harter P , Du Bois A . Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006 Dec;13(12):1702–1710.
   PubMed Web of Science ®Google Scholar
• Harter P , Sehouli J , Reuss A , et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011 Feb;21(2):289–295.
   PubMed Web of Science ®Google Scholar
• Tian WJ , Chi DS , Sehouli J , et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012 Feb;19(2):597–604.
   PubMed Web of Science ®Google Scholar
• van de Laar R , Massuger LF , Van Gorp T , et al. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2015 May;137(2):210–215.
   PubMed Web of Science ®Google Scholar
• Chi DS , Eisenhauer EL , Zivanovic O , et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009 Jul;114(1):26–31.
   PubMed Web of Science ®Google Scholar
• Aletti GD , Dowdy SC , Gostout BS , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006 Jan;107(1):77–85.
   PubMed Web of Science ®Google Scholar
• Hall M , Savvatis K , Nixon K , et al. Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome. Ann Surg Oncol. 2019 Sep;26(9):2943–2951.
   PubMed Web of Science ®Google Scholar
• Portilla AG , Shigeki K , Dario B , et al. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):228–231.
   PubMed Web of Science ®Google Scholar
• Engbersen MP , Van’ T , Sant I , et al. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. Eur J Radiol. 2019;114:146–151.
   PubMed Web of Science ®Google Scholar
• Garcia Prado J , González Hernando C , Varillas Delgado D , et al. Diffusion-weighted magnetic resonance imaging in peritoneal carcinomatosis from suspected ovarian cancer: diagnostic performance in correlation with surgical findings. Eur J Radiol. 2019;121:108696.
   PubMed Web of Science ®Google Scholar
• Llueca A , Serra A , Rivadulla I , et al. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index. World J Surg Oncol. 2018 Feb 23;16(1):37.
   PubMedGoogle Scholar
• Zanon C , Clara R , Chiappino I , et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg. 2004 Oct;28(10):1040–1045.
   PubMed Web of Science ®Google Scholar
• Di Giorgio A , Naticchioni E , Biacchi D , et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008 Jul 15;113(2):315–325.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos PA , Mῦnoz-Casares FC , Gonzalez-Gil A , et al. Upfront citorreduction and hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with stage III-C serous epithelial ovarian cancer. Clin Exp Metastasis. 2019. DOI: 10.1007/s10585-019-10010-5. Epub ahead of print.
   PubMedGoogle Scholar
• Le Saux O , Decullier E , Freyer G , et al. Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Hyperthermia. 2018;35(1):652–657.
   PubMed Web of Science ®Google Scholar
• Tentes AA , Kakolyris S , Kyziridis D , et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer. J Oncol. 2012;2012:358341.
   PubMedGoogle Scholar
• Arjona-Sanchez A , Rufián-Peña S . Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume centre. Int J Hyperthermia. 2017 Aug;33(5):554–561.
   PubMed Web of Science ®Google Scholar
• Pelz JO , Stojadinovic A , Nissan A , et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009 Jan 1;99(1):9–15.
   PubMed Web of Science ®Google Scholar
• Foster JM , Sleightholm R , Smith L , et al. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: an introduction of the peritoneal surface disease severity score. J Surg Oncol. 2016 Dec;114(7):779–784.
   PubMed Web of Science ®Google Scholar
• Yarema R , Fetsych T , Volodko N , et al. Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: two pathogenetic types based study. J Surg Oncol. 2018 Jun;117(8):1806–1812.
   PubMed Web of Science ®Google Scholar
• Gómez-Ruiz ÁJ , González-Gil A , Gil J , et al. Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC. Clin Exp Metastasis. 2019 Oct;36(5):433–439.
   PubMed Web of Science ®Google Scholar
• Pedro Antonio CC , Álvaro Jesús GR , José G , et al. Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Surg Oncol. 2019;28:57–61.
   PubMed Web of Science ®Google Scholar
• Lesnock JL , Darcy KM , Tian C , et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 2013 Apr 2;108(6):1231–1237.
   PubMed Web of Science ®Google Scholar
• Safra T , Grisaru D , Inbar M , et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol. 2014 Nov;110(6):661–665.
   PubMed Web of Science ®Google Scholar
• Patch AM , Christie EL , Etemadmoghadam D , et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28;521(7553):489–494.
   PubMed Web of Science ®Google Scholar
• Biacchi D , Accarpio F , Ansaloni L , et al. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC. J Surg Oncol. 2019 Dec;120(7):1208–1219.
   PubMed Web of Science ®Google Scholar
• Armstrong DK , Alvarez RD , Bakkum-Gamez JN , et al. NCCN guidelines insights: ovarian cancer, version 1.2019. J Natl Compr Canc Netw. 2019 Aug 1;17(8):896–909.
   PubMed Web of Science ®Google Scholar